<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491244</url>
  </required_header>
  <id_info>
    <org_study_id>200703010M</org_study_id>
    <nct_id>NCT00491244</nct_id>
  </id_info>
  <brief_title>Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C</brief_title>
  <official_title>Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Versus Pegylated Interferon Alfa-2a Alone for Treatment-naïve Hemodialysis Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Health, Executive Yuan, R.O.C. (Taiwan)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic hepatitis C virus (HCV) infection is common in dialysis patients. Interferon
      (IFN)-based treatment for chronic hepatitis C has been the mainstay therapy in
      immunocompetent patients. In dialysis patients, treatment with conventional or pegylated
      interferon has also received much attention recently. Two meta-analyses evaluating the
      efficacy and safety of conventional IFN alfa monotherapy showed that the sustained virologic
      response (SVR) rates were 37% and 33%, respectively; and the corresponding dropout rates were
      17% and 29.6%, respectively.The efficacy and safety of pegylated IFN alfa-2a and 2b in
      treating dialysis patients showed conflicting results, with a more favorable outcome of
      patients treated with pegylated IFN alfa-2a (135-180 μg/week: SVR 33-75%, well tolerated)
      than those treated with pegylated IFN alfa-2b (0.5-1.0 μg/week: SVR 12.5%, poorly tolerated.
      Currently, IFN-based therapy to treatment HCV infection should be initiated in dialysis
      stages, because the use of IFN in RT patients harbors high risks of acute graft rejection,and
      have low response rates under the concomitant use of immunosuppressive agents.

      Ribavirin, which has been used in combination with IFN to treat chronic hepatitis C in the
      general patients and achieve a higher SVR rate than IFN monotherapy, is considered
      contraindicated in dialysis patients with chronic hepatitis C due to the risk of severe
      hemolytic anemia. However, some pilot studies evaluating combined conventional IFN alfa plus
      low dose ribavirin (170-300 mg/day) showed SVR rates of 17%-66% after 24-48 weeks of
      treatment. In addition, a recent study including 6 patients with combination of pegylated IFN
      alfa plus low dose ribavirin also showed a SVR rate of 50%. In this study, treatment with
      pegylated IFN alfa-2a plus low dose ribavirin achieved a higher SVR rate that that with
      pegylated IFN alfa-2b plus low dose ribavirin (100% vs. 25%).

      Based on the long-term favorable outcome in dialysis patients who eradicate HCV, and the
      superior response of pegylated IFN alfa-2a plus low dose ribavirin to pegylated IFN alfa-2b
      plus low dose ribavirin in treating dialysis patients with chronic hepatitis C, the aim of
      the study is to evaluate the efficacy and safety of pegylated IFN alfa-2a plus low dose
      ribavirin versus pegylated interferon alfa-2a alone in treatment naïve dialysis patients with
      chronic hepatitis C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis C virus (HCV) infection is common in dialysis patients, with the reported
      prevalence varying from 3% to 80% worldwide. (1-3) Although these patients usually have mild
      symptoms and moderate elevation of alanine transaminase levels, recent international
      collaborative survey and prospective studies found that anti-HCV seropositivity and positive
      HCV RNA were risk factors for mortality and hepatocellular carcinoma (HCC). (4-7)
      Furthermore, progressive hepatic fibrosis, poor patient and graft survival were observer in
      dialysis patients with HCV infection who undergo renal transplantation (RT), suggesting
      immunosuppression following RT may worsen the course of hepatic fibrosis and renal graft
      function. (8-13) These lines of evidence indicate that HCV infection in the dialysis
      population is an important issue to be tackled.

      Interferon (IFN)-based treatment for chronic hepatitis C has been the mainstay therapy in
      immunocompetent patients. In dialysis patients, treatment with conventional or pegylated
      interferon has also received much attention recently. Two meta-analyses evaluating the
      efficacy and safety of conventional IFN alfa monotherapy showed that the sustained virologic
      response (SVR) rates were 37% and 33%, respectively; and the corresponding dropout rates were
      17% and 29.6%, respectively.(14,15) The efficacy and safety of pegylated IFN alfa-2a and 2b
      in treating dialysis patients showed conflicting results, with a more favorable outcome of
      patients treated with pegylated IFN alfa-2a (135-180 μg/week: SVR 33-75%, well tolerated)
      than those treated with pegylated IFN alfa-2b (0.5-1.0 μg/week: SVR 12.5%, poorly tolerated),
      (16-21) which may result from different pharmacokinetic profiles between these two pegylated
      IFNs. Currently, IFN-based therapy to treatment HCV infection should be initiated in dialysis
      stages, because the use of IFN in RT patients harbors high risks of acute graft
      rejection,(22,23) and have low response rates under the concomitant use of immunosuppressive
      agents. (24,25) Ribavirin, which has been used in combination with IFN to treat chronic
      hepatitis C in the general patients and achieve a higher SVR rate than IFN monotherapy, is
      considered contraindicated in dialysis patients with chronic hepatitis C due to the risk of
      severe hemolytic anemia. However, some pilot studies evaluating combined conventional IFN
      alfa plus low dose ribavirin (170-300 mg/day) showed SVR rates of 17%-66% after 24-48 weeks
      of treatment. (26-28) In addition, a recent study including 6 patients with combination of
      pegylated IFN alfa plus low dose ribavirin also showed a SVR rate of 50%. (29) In this study,
      treatment with pegylated IFN alfa-2a plus low dose ribavirin achieved a higher SVR rate that
      that with pegylated IFN alfa-2b plus low dose ribavirin (100% vs. 25%) Based on the long-term
      favorable outcome in dialysis patients who eradicate HCV, and the superior response of
      pegylated IFN alfa-2a plus low dose ribavirin to pegylated IFN alfa-2b plus low dose
      ribavirin in treating dialysis patients with chronic hepatitis C, the aim of the study is to
      evaluate the efficacy and safety of pegylated IFN alfa-2a plus low dose ribavirin versus
      pegylated interferon alfa-2a in treatment naïve dialysis patients with chronic hepatitis C.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response (SVR)Rate</measure>
    <time_frame>1.5 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event (AE)-Related Withdrawal Rate</measure>
    <time_frame>1.5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">377</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Peginterferon alfa-2a and ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon alfa-2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a and ribavirin</intervention_name>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)</description>
    <arm_group_label>Peginterferon alfa-2a and ribavirin</arm_group_label>
    <other_name>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche)</other_name>
    <other_name>Ribavirin (Copegus, F. Hoffman-LaRoche)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)</description>
    <arm_group_label>Peginterferon alfa-2a</arm_group_label>
    <other_name>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years old

          -  Creatinine clearance (Ccr) &lt; 15 ml/min/1.73 m2

          -  Anti-HCV (Abbott HCV EIA 3.0, Abbott Diagnostic, Chicago, IL) positive &gt; 6 months

          -  Detectable serum quantitative HCV-RNA (Cobas Taqman HCV test, version 2, Roche
             Diagnostics) with a dynamic range of 25-391000000 IU/ml

        Exclusion Criteria:

          -  Receiving interferon-based therapy for chronic hepatitis C

          -  Severe anemia (hemoglobin &lt; 10 g/dL) or hemoglobinopathy

          -  Neutropenia (neutrophil count, &lt;1,500/mm3)

          -  Thrombocytopenia (platelet &lt;90,000/ mm3)

          -  Co-infection with HBV or HIV

          -  Chronic alcohol abuse (daily consumption &gt; 20 g/day)

          -  Autoimmune liver disease

          -  Decompensated liver disease (Child classification B or C)

          -  Neoplastic disease

          -  An organ transplant

          -  Immunosuppressive therapy

          -  Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases,
             psychiatric diseases, neurological diseases, diabetes mellitus

          -  Evidence of drug abuse

          -  Unwilling to have contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen-Hua Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Internal Medicine, National Taiwan Universitys Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002 Jul;36(1):3-10. Review.</citation>
    <PMID>12085342</PMID>
  </reference>
  <reference>
    <citation>Kao JH, Huang CH, Chen W, Tsai TJ, Lee SH, Hung KY, Chen DS. GB virus C infection in hemodialysis patients: molecular evidence for nosocomial transmission. J Infect Dis. 1999 Jul;180(1):191-4.</citation>
    <PMID>10353878</PMID>
  </reference>
  <reference>
    <citation>Hou CH, Chen WY, Kao JH, Chen DS, Yang Y, Chen JJ, Lee SH, Wu DJ, Yang SC. Intrafamilial transmission of hepatitis C virus in hemodialysis patients. J Med Virol. 1995 Apr;45(4):381-5.</citation>
    <PMID>7545208</PMID>
  </reference>
  <reference>
    <citation>Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999 Jul 10;354(9173):93-9.</citation>
    <PMID>10408483</PMID>
  </reference>
  <reference>
    <citation>Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000 Oct;11(10):1896-902.</citation>
    <PMID>11004221</PMID>
  </reference>
  <reference>
    <citation>Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis. 1998 Oct;32(4):629-34.</citation>
    <PMID>9774125</PMID>
  </reference>
  <reference>
    <citation>Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1998 May;53(5):1374-81.</citation>
    <PMID>9573555</PMID>
  </reference>
  <reference>
    <citation>Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999 Jan;29(1):257-63.</citation>
    <PMID>9862875</PMID>
  </reference>
  <reference>
    <citation>Legendre C, Garrigue V, Le Bihan C, Mamzer-Bruneel MF, Chaix ML, Landais P, Kreis H, Pol S. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation. 1998 Mar 15;65(5):667-70.</citation>
    <PMID>9521201</PMID>
  </reference>
  <reference>
    <citation>Vosnides GG. Hepatitis C in renal transplantation. Kidney Int. 1997 Sep;52(3):843-61.</citation>
    <PMID>9291208</PMID>
  </reference>
  <reference>
    <citation>Izopet J, Rostaing L, Sandres K, Cisterne JM, Pasquier C, Rumeau JL, Duffaut M, Durand D, Puel J. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis. 2000 Mar;181(3):852-8.</citation>
    <PMID>10720504</PMID>
  </reference>
  <reference>
    <citation>Zylberberg H, Nalpas B, Carnot F, Skhiri H, Fontaine H, Legendre C, Kreis H, Bréchot C, Pol S. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant. 2002 Jan;17(1):129-33.</citation>
    <PMID>11773476</PMID>
  </reference>
  <reference>
    <citation>Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther. 2003 Dec;18(11-12):1071-81. Review.</citation>
    <PMID>14653826</PMID>
  </reference>
  <reference>
    <citation>Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol. 2003 Jul;98(7):1610-5. Review.</citation>
    <PMID>12873587</PMID>
  </reference>
  <reference>
    <citation>Kokoglu OF, Uçmak H, Hosoglu S, Cetinkaya A, Kantarceken B, Buyukbese MA, Isik IO. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006 Mar;21(3):575-80.</citation>
    <PMID>16638102</PMID>
  </reference>
  <reference>
    <citation>Sporea I, Popescu A, Sirli R, Golea O, Totolici C, Danila M, Vernic C. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol. 2006 Jul 14;12(26):4191-4.</citation>
    <PMID>16830372</PMID>
  </reference>
  <reference>
    <citation>Chan TM, Ho SK, Tang CS, Tse KC, Lam MF, Lai KN, Yung S. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology (Carlton). 2007 Feb;12(1):11-7.</citation>
    <PMID>17295655</PMID>
  </reference>
  <reference>
    <citation>Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2006 Feb;21(2):437-43. Epub 2005 Oct 18.</citation>
    <PMID>16234288</PMID>
  </reference>
  <reference>
    <citation>Annicchiarico BE, Siciliano M. Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Aliment Pharmacol Ther. 2004 Jul 1;20(1):123-4; author reply 124.</citation>
    <PMID>15225179</PMID>
  </reference>
  <reference>
    <citation>Potthoff A, Wiegand J, Lüth JB, Wedemeyer H, Manns MP, Tillmann HL. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? Clin Nephrol. 2005 Mar;63(3):232-5.</citation>
    <PMID>15786827</PMID>
  </reference>
  <reference>
    <citation>Magnone M, Holley JL, Shapiro R, Scantlebury V, McCauley J, Jordan M, Vivas C, Starzl T, Johnson JP. Interferon-alpha-induced acute renal allograft rejection. Transplantation. 1995 Apr 15;59(7):1068-70.</citation>
    <PMID>7709447</PMID>
  </reference>
  <reference>
    <citation>Morales JM. Hepatitis C virus infection and renal disease after renal transplantation. Transplant Proc. 2004 Apr;36(3):760-2. Review.</citation>
    <PMID>15110654</PMID>
  </reference>
  <reference>
    <citation>Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant alpha 2b interferon in kidney transplant recipients: preliminary results and side effects. Transplant Proc. 1995 Feb;27(1):948-50.</citation>
    <PMID>7879242</PMID>
  </reference>
  <reference>
    <citation>Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano TT, Casanova A, Pérez JL, Guerrero L, González MT, Andres E, Gil-Vernet S, Casais LA. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol. 2001 Apr;96(4):1170-7.</citation>
    <PMID>11316166</PMID>
  </reference>
  <reference>
    <citation>Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc. 2004 Jul-Aug;36(6):1831-4.</citation>
    <PMID>15350490</PMID>
  </reference>
  <reference>
    <citation>Bruchfeld A, Ståhle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study. J Viral Hepat. 2001 Jul;8(4):287-92.</citation>
    <PMID>11454181</PMID>
  </reference>
  <reference>
    <citation>Bruchfeld A, Ståhle L, Andersson J, Schvarcz R. Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2001 Aug;16(8):1729.</citation>
    <PMID>11477195</PMID>
  </reference>
  <reference>
    <citation>Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat. 2006 May;13(5):316-21.</citation>
    <PMID>16637862</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2007</study_first_submitted>
  <study_first_submitted_qc>June 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <results_first_submitted>September 29, 2013</results_first_submitted>
  <results_first_submitted_qc>September 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2013</results_first_posted>
  <last_update_submitted>January 13, 2014</last_update_submitted>
  <last_update_submitted_qc>January 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Interferon</keyword>
  <keyword>Ribavirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from 1 June, 2007 to 9 May, 2012 Location: 8 academic centers in Taiwan</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Peginterferon and Ribavirin</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)</description>
        </group>
        <group group_id="P2">
          <title>Peginterferon</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peginterferon and Ribavirin</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)</description>
        </group>
        <group group_id="B2">
          <title>Peginterferon</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="189"/>
            <count group_id="B2" value="188"/>
            <count group_id="B3" value="377"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="10"/>
                    <measurement group_id="B2" value="51" spread="11"/>
                    <measurement group_id="B3" value="51" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Virologic Response (SVR)Rate</title>
        <time_frame>1.5 year</time_frame>
        <population>All participants were analyzed if they received at least one dose of the study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Ribavirin</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response (SVR)Rate</title>
          <population>All participants were analyzed if they received at least one dose of the study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.46</ci_lower_limit>
            <ci_upper_limit>2.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event (AE)-Related Withdrawal Rate</title>
        <time_frame>1.5 year</time_frame>
        <population>All patients were analyzed if they received at least one dose of the study medication; monitoring the events until the last visit</population>
        <group_list>
          <group group_id="O1">
            <title>Peginterferon and Ribavirin</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Peginterferon</title>
            <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event (AE)-Related Withdrawal Rate</title>
          <population>All patients were analyzed if they received at least one dose of the study medication; monitoring the events until the last visit</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Advese event related withdrawal rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>4.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Peginterferon and Ribavirin</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)</description>
        </group>
        <group group_id="E2">
          <title>Peginterferon</title>
          <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>DAIDS AE grade table</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Postural dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intractable diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Peptic ulcer bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Salmonella gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens-Johnson sybdrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>DAIDS AE grade table</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Hemoglobin level &lt; 8.5 g/dL</description>
                <counts group_id="E1" events="134" subjects_affected="134" subjects_at_risk="189"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Absolute neutrophil count &lt; 750 x 10^9 cells/L</description>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="189"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Platelet count &lt; 50 x 10^9 cells/L</description>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="189"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="189"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="189"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="189"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="189"/>
                <counts group_id="E2" events="50" subjects_affected="50" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="106" subjects_affected="106" subjects_at_risk="189"/>
                <counts group_id="E2" events="97" subjects_affected="97" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="189"/>
                <counts group_id="E2" events="48" subjects_affected="48" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="62" subjects_affected="62" subjects_at_risk="189"/>
                <counts group_id="E2" events="66" subjects_affected="66" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="189"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="189"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="189"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="189"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="189"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="189"/>
                <counts group_id="E2" events="43" subjects_affected="43" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Open-label trial
Results may not be generalizable to peritoneal dialysis patients
Higher percentages of favorable IL28B genotypes
Secondary endpoint may not be powered to detect the differences</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Chen-Hua Liu</name_or_title>
      <organization>National Taiwan University Hospital</organization>
      <phone>+886-2-23123456 ext 63572</phone>
      <email>jacque_liu@mail2000.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

